Periodic Reporting for period 2 - SkinMicrobiome (Paradigm Change in Skin Health: Novel Microbiome-based Cosmetics for Acne and Other Skin Conditions)
Periodo di rendicontazione: 2021-02-01 al 2022-01-31
S -Biomedic has developed a disruptive technology to directly modulate the skin microbiome, enabling a wide range of applications in dermatology. The first product is a cosmetic for acne-prone skin with proven efficacy and safety in an area where competing products are either ineffective or cause severe side effects.
Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology, and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline.
The SkinMicrobiome project supports S-Biomedic in the route to market and accelerates the company growth, enabling positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome allows to hire employees with commercial and marketing background, who complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome is a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology, and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline.
The SkinMicrobiome project supports S-Biomedic in the route to market and accelerates the company growth, enabling positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome allows to hire employees with commercial and marketing background, who complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome is a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Within the 24 months of the SkinMicrobiome project we have achieved all defined objectives and successfully placed a novel LiveSkin Probiotic skincare product in the European market. The work included initial market research that enabled us to understand the consumer problem from all different aspects. The core of these learnings served as a base for product development, branding, and marketing strategy.
The product concept has been elaborated and then developed into a product prototype that has undergone multiple testing. These included technical tests, stability, compatibility of ingredients, formulation, and packaging. Further manufacturing pilot tests combined with labelling and packaging print tests. The product prototypes were also tested in consumer studies and extensive clinical studies to confirm the market fit and substantiate the claims for registration in the European market.
Ultimately marketing strategy and go-to-market plan were elaborated and executed. The products were placed in the market via Direct to Consumer online channel (webshop) with social media serving as sales, communication, and dissemination platforms. The intellectual property of the brand and the live probiotics has been protected via multiple trademarks, while the technology itself already relies on various patent filings.
The product concept has been elaborated and then developed into a product prototype that has undergone multiple testing. These included technical tests, stability, compatibility of ingredients, formulation, and packaging. Further manufacturing pilot tests combined with labelling and packaging print tests. The product prototypes were also tested in consumer studies and extensive clinical studies to confirm the market fit and substantiate the claims for registration in the European market.
Ultimately marketing strategy and go-to-market plan were elaborated and executed. The products were placed in the market via Direct to Consumer online channel (webshop) with social media serving as sales, communication, and dissemination platforms. The intellectual property of the brand and the live probiotics has been protected via multiple trademarks, while the technology itself already relies on various patent filings.
The new concept of skin probiotics is completely novel in the cosmetic and skin care industry. In the past years we can observe increase of probiotic and microbiome claims in the industry, however, most of these are based on food probiotics. This means that probiotics used in the gut are re-branded for the use on the skin. S-Biomedic pioneers the use of natural skin beneficial bacteria in skin care. After the initial application in acne, the concept is suitable to help people with many skin conditions ranging from sensitive skin, atopic dermatitis to dandruff.
With close to 700 million people affected by acne worldwide, the SkinMicrobiome project will have an enormous impact on the quality of life of acne-prone people. Our solution will provide an effective solution free of side effects, which should contribute to mitigating the psychological issues associated with this condition, such as anxiety, depression, and low self-esteem. This is especially relevant for the development of healthy social life in teenagers, a very vulnerable group. Our solution will also contribute to reducing the physical sequelae (scars) caused by the disease, as the early application of our cosmetic will reduce the number of severely affected cases.
Our product will contribute to avoiding some of the serious side-effects of acne drugs that include severely dry skin, skin hypersensitivity, muscle pain, joint pain, dry eye, and even birth defects.
According to the World Health Organization, the growth of antibiotic resistance has become a global challenge leading to higher medical costs, prolonged hospital stays and increased mortality. Antibiotic resistance is raising to dangerously high levels across the globe. New resistance mechanisms are emerging and spreading globally. According to the experts, we need to change the way antibiotics are prescribed and used. Given the wide use of antibiotics for acne treatment and its high prevalence, the market uptake of our acne skin probiotic shall help to reduce the consumption and disposal of antibiotics across the world, contributing to this highly important issue with direct links to sustainable development goals such as health and the conservation of natural resources and the environment.
With close to 700 million people affected by acne worldwide, the SkinMicrobiome project will have an enormous impact on the quality of life of acne-prone people. Our solution will provide an effective solution free of side effects, which should contribute to mitigating the psychological issues associated with this condition, such as anxiety, depression, and low self-esteem. This is especially relevant for the development of healthy social life in teenagers, a very vulnerable group. Our solution will also contribute to reducing the physical sequelae (scars) caused by the disease, as the early application of our cosmetic will reduce the number of severely affected cases.
Our product will contribute to avoiding some of the serious side-effects of acne drugs that include severely dry skin, skin hypersensitivity, muscle pain, joint pain, dry eye, and even birth defects.
According to the World Health Organization, the growth of antibiotic resistance has become a global challenge leading to higher medical costs, prolonged hospital stays and increased mortality. Antibiotic resistance is raising to dangerously high levels across the globe. New resistance mechanisms are emerging and spreading globally. According to the experts, we need to change the way antibiotics are prescribed and used. Given the wide use of antibiotics for acne treatment and its high prevalence, the market uptake of our acne skin probiotic shall help to reduce the consumption and disposal of antibiotics across the world, contributing to this highly important issue with direct links to sustainable development goals such as health and the conservation of natural resources and the environment.